sym022
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 7, 2017 (NCT03311412)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04641871 | Phase 1 | Oct 12, 2020 | START Midwest, Symphogen A/S |
| NCT03489369 | Phase 1 | May 8, 2018 | Symphogen A/S, University of Toronto |
| NCT03311412 | Phase 1 | Dec 7, 2017 | Symphogen A/S, University of Toronto |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Symphogen A/S | For profit | 3 | 3 | 1 | 2017 |
| University of Toronto | Academic/Hospital | 2 | 0 | 1 | 2017 |
| START Midwest | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1